JommiC. and CavazzaM. (2019) “Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals”, Global & Regional Health Technology Assessment, 6(1). doi: 10.33393/grhta.2019.460.